|
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
Jul 2023 |
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
|
Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
Dec 2023 |
Immunotherapy |
Aplastic Anemia |
|
Pitfalls in Assessing Response to Treatment in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Mar 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Aug 2023 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy |
Oct 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
Jun 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
